RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode

Phase 2Active Not RecruitingNCT03870776

Mapreg110 enrolled

Overview

The study is a phase II, double-blind, randomized, placebo controlled, parallel, multicentric study in 110 patients with drug resistant depression.

This is a phase II, versus placebo, multicentre, double blind, randomized, parallel study in male or female patients with drug resistant depression. This study targets the antidepressant non-responders' patients who have already experienced at least 2 antidepressant treatments with no success. It is estimated that about 2/3 of the patients treated with antidepressant drugs do not respond partially or completely to the actual conventional treatments (Selective Serotonin Reuptake Inhibitor and Serotonin and Norepinephrine Reuptake Inhibitor). 110 patients with drug resistant depression episode, aged 18 to 80 will be included in the study. They will be recruited from psychiatric consultations in the centers participating to the study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

110

Conditions

Depression

Interventions

MAP4343DRUG

Daily oral administration of MAP4343

PlaceboDRUG

Daily oral administration of Placebo

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. TRD level from to 2 to 4 inclusive according to the Thase \& Rush classification; 2. Patient experiencing a Major Depressive Episode (MDE) according to DSM-5 criteria. MDE can be isolated or recurrent. The diagnosis is based on Mini-International Neuropsychiatric Interview (MINI) test; 3. Patient who received a previous antidepressant treatment (AD-Y) in monotherapy with vortioxetine, duloxetine or venlafaxine) at optimized dosages during 6 weeks prior to randomization, associated or not to AD-potentiator (quetiapine), are eligible. 4. Hamilton Depression Rating Scale (HDRS) score \> 21; 5. Clinical Global Impressions scale (CGI) ≥ 4; 6. Male or female patient, aged 18 to 80 years inclusive; 7. Females of childbearing potential/Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices, diaphragm or condoms) for the duration of the trial and for 4 months after the last study drug administration; Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months); 8. Negative pregnancy test at screening baseline; 9. Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive; 10. Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests, urinalysis, hormonology). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator; 11. Normal ECG recording on a 12-lead ECG at the screening visit: * 120 \< PR \< 210 ms * QRS \< 120 ms * QTcF ≤ 430 ms for male and \< 450 ms for female, * No sign of any trouble of sinusal automatism, * Or considered NCs by investigators; 12. Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes in supine position: * 95 mmHg ≤ Systolic Blood Pressure (SBP) ≤ 140 mmHg, * 50 mmHg ≤ Diastolic Blood Pressure (DBP) ≤ 90 mmHg, * 50 bpm ≤ HR ≤ 80 bpm, * Or considered NCs by investigators; 13. Signing a written informed consent prior to selection; 14. Covered by Health Insurance System and/or in compliance with the recommendations of National Law in force relating to biomedical research. Exclusion Criteria: 1. MDE with mood congruent or not congruent psychotic characteristics; 2. Patient hospitalized following the procedures: Psychiatric care at the request of another person (soins psychiatriques à la demande d'un tiers) or Psychiatric care at the request of the state representative (soins psychiatriques sur décision du représentant de l'Etat); 3. Suicidal risk in the last month before randomization (C-SSRS: answer yes to the item 3 and/or answer yes to section suicidal behavior; MINI 5.00; suicidal risk section or item 3 of HDRS ≥ 3); 4. History of other psychiatric disorder than DME except global anxiety, social phobia, panic troubles that should be accepted. In particular, patients who experienced a depressive state in bipolar disorder 1 or 2, schizophrenic or schizoaffective disorder should not be included; 5. Presence or history of drug hypersensitivity, or certain allergic-prone condition diagnosed that could represent a risk factor for an allergic shock; 6. Presence or history of hypersensitivity to vortioxetine, duloxetine, venlafaxine or one of their excipients; 7. Any history or presence of severe hepatic insufficiency and/or of hepatic disease which could lead to hepatic insufficiency; 8. Patients who are pregnant or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the time of study participation; 9. Any drug intake during the last month prior to the first administration except treatments for concomitant pathologies which are stable since at least 3 months; Benzodiazepine-type anxiolytics, hydroxyzine chlorhydrate, and add-on treatments are authorized within limits described in Section 5.3; For the previous drug intake, the investigator should consider the time needed to sufficiently eliminate a drug from body system, e.g. 5 half-lives of the drug; 10. Subjects who received MAOI in monotherapy right before the selection (as ttX); 11. General anesthesia within 3 months before administration; 12. Major surgery within 28 days prior to randomization or major surgery planned during the next 6 months; 13. Positive HBs antigen or anti HCV antibody, or positive results for HIV 1 or 2 tests; 14. Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant, calculated creatinine clearance ≤ 60 mL/min; 15. Blood donation (including in the frame of a clinical trial) within 2 months before administration; 16. Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development; 17. Medical history which in the opinion of the investigator would make the patient unsuitable for participation in the study (including, but not limited, to patients with coronary insufficiency, thromboembolism diseases); 18. Exclusion period of a previous study; 19. No possibility of contact in case of emergency; 20. History or presence of drug or alcohol abuse (alcohol consumption \> 40 g/day); 21. Administrative or legal supervision.

Locations (10)

CHU Angers

Angers, France

CHU Besançon

Besançon, France

Cabinet Médical Ambroise Paré

Élancourt, France

CHD Vendée

La Roche-sur-Yon, France

Outcomes

Primary Outcomes

Hamilton Depression Rating Scale score evolution between baseline and D43

Assessment of HDRS score with 17 items with sides 0 to 2 or 0 to 4. The scores from 0 to 4 correspond respectively to symptoms: absent, doubtful or insignificant, light, moderate, important, those ranging from 0 to 2 to symptoms: absent, doubtful or slight, overt or severe. The total score consists of the addition of the individual scores.

Time frame: 43 days

Secondary Outcomes

Efficacy of treatment assessed by psychopathological evaluations with Hamilton Depression Rating Scale

psychopathological evaluations at each study visit: Hamilton Depression Rating Scale (17 items with sides 0 to 2 or 0 to 4. The scores from 0 to 4 correspond respectively to symptoms: absent, doubtful or insignificant, light, moderate, important, those ranging from 0 to 2 to symptoms: absent, doubtful or slight, overt or severe. The total score consists of the addition of the individual scores)

Time frame: 43 days

Efficacy of treatment assessed by psychopathological evaluations with Montgomery and Asberg Depression rating Scale

psychopathological evaluations at each study visit:Montgomery and Asberg Depression rating Scale used to quatify the intensity of depressive symptomatology

Time frame: 43 days

Efficacy of treatment assessed by psychopathological evaluations with Brief Anxiety Scale

psychopathological evaluations at each study visit: Brief Anxiety Scale, a dimensional measure of generalized anxiety with 8 items

Time frame: 43 days

Efficacy of treatment assessed by psychopathological evaluations with Scale of Global Clinical Impressions

psychopathological evaluations at each study visit: Scale of Global Clinical Impressions which includes 2 items rated from 1 to 7 (first item is a measurement of the overall measurement of patient's condition; 2nd item evaluates the overall improvementof patient compared to his condition at the admission to the research

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Hôpital Fontan 1

Lille, France

CHU Nantes

Nantes, France

APHP Hôpital La Pitié Salpétrière - Prinicipal investigator center

Paris, France

Hôpital Ste Anne

Paris, France

CHU Henri Laborit

Poitiers, France

CHRU Tours

Tours, France

Efficacy of treatment assessed by psychopathological evaluations with Quick Inventory of Depressive Symptoms

psychopathological evaluations at each study visit: Quick Inventory of Depressive Symptoms is a questionnaire allowing the assessment of the degree of depression by the patient himself.

Time frame: 43 days

Efficacy of treatment assessed by psychopathological evaluations with General Assessment Functioning

psychopathological evaluations at each study visit: General Assessment Functioning. The score is ranged on a hypothetical continuum from 1, the value representing the sickest individual, to 90, a value representing an individual without or with very minimal symptoms and functioning satisfactorily in his social environment or his family. The scale is divided into 9 equal intervals ranging from 1 to 10, 11 to 20, 21 to 30, etc.

Time frame: 43 days

Pharmacokinetic assessments with observed maximum plasma concentration (Cmax);

Cmax for MAP4343 in plasma at each study visit.

Time frame: 127 days

Pharmacokinetic assessments with first time to reach Cmax (tmax);

tmax for MAP4343 in plasma at each study visit.

Time frame: 127 days

Pharmacokinetic assessments with elimination rate constant (Kel);

Kel for MAP4343 in plasma at each study visit.

Time frame: 127 days

Pharmacokinetic assessments with plasma elimination half-life (t1/2);

t1/2 for MAP4343 in plasma at each study visit

Time frame: 127 days

Pharmacokinetic assessments with plasma area under the plasma concentration-time curve from administration up to infinity with extrapolation of the terminal phase (AUCinf);

AUCinf for MAP4343 in plasma at each study visit

Time frame: 127 days

Pharmacokinetic assessments with percentage of extrapolated AUCinf (%AUCextra);

%AUCextra for MAP4343 in plasma at each study visit

Time frame: 127 days

Pharmacokinetic assessments with volumn of distribution (Vd/F);

Vd/F for MAP4343 in plasma at each study visit.

Time frame: 127 days

Pharmacokinetic assessments with Clearance (Cl/F);

Cl/F for MAP4343 in plasma at each study visit

Time frame: 127 days

Pharmacokinetic assessments with accumulation ratio (R);

R for MAP4343 in plasma at each study visit.

Time frame: 127 days

Safety parameters assessed by the number of adverse events (AE)

AE evaluation

Time frame: 127 days

Safety parameters assessed - Heart rate

Vital signs assessed by heart rate measurement (beats per minute)

Time frame: 127 days

Safety parameters assessed by blood pressure

Vital signs assessed by systolic and diastolic blood pressure measurement (mmHg)

Time frame: 127 days

Safety parameters assessed - 12-lead Electrocardiogramm

Heart Rate; Electrocardiogramm measure during 12 hours (12-lead ECG) : heart rate (beats per minute)

Time frame: 127 days

Safety parameters assessed - 12-lead ElectrocardiogrammPR;

Electrocardiogramm measure during 12 hours (12-lead ECG) : PR interval (milliseconds)

Time frame: 127 days

Safety parameters assessed -12-lead Electrocardiogramm : QT

Electrocardiogramm measure during 12 hours (12-lead ECG) : QT interval (milliseconds)

Time frame: 127 days

Safety parameters assessed - 12-lead Electrocardiogramm : QTc

Electrocardiogramm measure during 12 hours (12-lead ECG) : QTc with automatic correction (milliseconds)

Time frame: 127 days

Safety parameters assessed by hematology parameters : Haemoglobin

Laboratory exams : hematology parameters (Haemoglobin in g/L)

Time frame: 127 days

Safety parameters assessed by hematology parameters: Haematocrit

Laboratory exams : hematology parameters (Haematocrit in %)

Time frame: 127 days

Safety parameters assessed by hematology parameters: Red blood cells

Laboratory exams : hematology parameters (Red blood cells in Tera/L)

Time frame: 127 days

Safety parameters assessed by hematology parameters: White blood cells

Laboratory exams : hematology parameters (White blood cells in Giga/L)

Time frame: 127 days

Safety parameters assessed by hematology parameters:Neutrophils

Laboratory exams : hematology parameters (Neutrophils in Giga/L

Time frame: 127 days

Safety parameters assessed by hematology parameters: Eosinophils

Laboratory exams : hematology parameters (Eosinophils in Giga/L)

Time frame: 127 days

Safety parameters assessed by hematology parameters: Basophils

Laboratory exams : hematology parameters (Basophils in Giga/L)

Time frame: 127 days

Safety parameters assessed by hematology parameters: Lymphocytes

Laboratory exams : hematology parameters (Lymphocytes in Giga/L)

Time frame: 127 days

Safety parameters assessed by hematology parameters: Monocytes

Laboratory exams : hematology parameters (Monocytes in Giga/L)

Time frame: 127 days

Safety parameters assessed by hematology parameters: Platelets

Laboratory exams : hematology parameters (Platelets in Giga/L)

Time frame: 127 days

Safety parameters assessed by hematology parameters: Reticulocytes;

Laboratory exams : hematology parameters (Reticulocytes in Giga/L)

Time frame: 127 days

Safety parameters assessed by red blood cells indices

MCV; Red blood cells indices : MCV (in picograms) MCH; Red blood cells indices : MCH (in picograms) MCHC; Red blood cells indices : MCHC (in picograms)

Time frame: 127 days

Safety parameters assessed by hemostasis parameters

INR measurement; Laboratory exams : hemostasis parameters (INR) Prothrombin time; Laboratory exams : hemostasis parameters (Prothrombin time in seconds) APTT; Laboratory exams : hemostasis parameters (APTT in seconds) APTT reference; Laboratory exams : hemostasis parameters (APTT reference in seconds)

Time frame: 127 days

Safety parameters assessed by serology parameters

P24 antigen; Laboratory exams : serology (P24 antigen detection) HIV; Laboratory exams : serology (HIV 1/2 antibodies detection) HCV; Laboratory exams : serology (HCV antibodies detection) HBs; Laboratory exams : serology (HBs antigen detection)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters : Glucose

Lab exams: biochem(Glucose in mmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: Creatinine

Lab exams: biochem( in μmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: SGOT/ASAT

Lab exams : biochem(in IU/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: SGOT/ALAT

Lab exams: biochem(in IU/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters:GGT

Lab exams: biochem(IU/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: Alkalin phosphatase

Lab exams: biochem(IU/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: CPK

Lab exams: biochem(IU/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: Total bilirubin

Lab exams: biochem(μmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: Conjugated bilirubin

Lab exams: biochem(μmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: Uric Acid

Lab exams: biochem(μmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: Cholesterol

Lab exams: biochem(in mmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: Triglycerides

Lab exams: biochem(in mmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: Sodium

Lab exams: biochem(in mmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: Potassium

Lab exams: biochem(in mmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters: Chlore

Lab exams: biochem( in mmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters:Calcium

Lab exams: biochem(in mmol/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters:Total protein

Lab exams: biochem(in g/L)

Time frame: 127 days

Safety parameters assessed by biochemistry parameters:Albumin

Lab exams: biochem(in g/L)

Time frame: 127 days

Safety parameters assessed by hormonology parameters

Laboratory exams : hormonology (Β-HCG)

Time frame: 127 days

Safety parameters assessed by weight measurement

Physical exams : weight measurement in kilograms

Time frame: 127 days

Safety parameters assessed by height measurement

Physical exams : height measurement in centimeters

Time frame: 127 days

Battery of cognitive tasks

Cognitive evaluation

Time frame: 43 days

Plasmatic quantification of inflammatory biomarkers concentration (CRPs)

Plasmatic quantification of concentration CRPs.

Time frame: 43 days

Plasmatic quantification of inflammatory biomarkers concentration (Interleukins1, 6 and 10)

Plasmatic quantification of concentration of Interleukins 1, 6 and 10

Time frame: 43 days

Blood quantification of gut microbiome

Metagenomic study of blood markers of gut mircrobiome

Time frame: 43